[£ £ £ £ Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. In accordance with NYSE procedures, the Company has six months from the receipt of the notice on March 30, 2012 to cure this deficiency. The Company can regain compliance at any time during the six-month cure period if]
[£ £ £ £ Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. In accordance with NYSE procedures, the Company has six months from the receipt of the notice on March 30, 2012 to cure this deficiency. The Company can regain compliance at any time during the six-month cure period if]
[ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF BIOSTAR PHARMACEUTICALS, INC. This is to certify that: FIRST SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Inc. Ronghua Wang Shuang Gong Chief Executive Officer Secretary EX-3.1 2 ex3-1.htm] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCK SPLIT -- XIANYANG, China, April 3, 2012 As a result of the reverse stock split, the number of outstanding common shares will be reduced to approximately 9,398,892. Fractional stockholdings will be rounded up to the nearest whole number. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder’s ownership]
[ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF BIOSTAR PHARMACEUTICALS, INC. This is to certify that: FIRST SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Inc. Ronghua Wang Shuang Gong Chief Executive Officer Secretary EX-3.1 2 ex3-1.htm] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCK SPLIT -- XIANYANG, China, April 3, 2012 As a result of the reverse stock split, the number of outstanding common shares will be reduced to approximately 9,398,892. Fractional stockholdings will be rounded up to the nearest whole number. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder’s ownership]
[ARTICLES OF AMENDMENT TO THE ARTICLES OFORPORATION OF BIOSTAR PHARMACEUTICALS, This is to certify that: SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Ronghua Wang Shuang Gong Chief Executive Officer Secretary ex3-1.htm 2 EX-3.1] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCKLIT -- XIANYANG, China, April 3, 2012 a result of the reverse stocklit, the number of outstandingmmon shares will be reduced to approximately 9,398,892.Fractional stockholdings will be rounded up to the nearest whole number.The reverse stocklit will affectl stockholders uniformly and will not affect any stockholders ownership percentage of the]
[ARTICLES OF AMENDMENT TO THE ARTICLES OFORPORATION OF BIOSTAR PHARMACEUTICALS, This is to certify that: SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Ronghua Wang Shuang Gong Chief Executive Officer Secretary ex3-1.htm 2 EX-3.1] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCKLIT -- XIANYANG, China, April 3, 2012 a result of the reverse stocklit, the number of outstandingmmon shares will be reduced to approximately 9,398,892.Fractional stockholdings will be rounded up to the nearest whole number.The reverse stocklit will affectl stockholders uniformly and will not affect any stockholders ownership percentage of the]
[China Housing & Land Development Inc. Announces Xi’an, China – March 30, 2012 Highlights for Q4 2011: · Total revenue in the fourth quarter of 2011 increased 49.2% to $47.9 million from $32.1 million in the third quarter of 2011 and increased 32.8% from $36.1 million in the fourth quarter of 2010. · Total gross floor area (“GFA”) sales were] []
[China Housing & Land Development Inc. Announces Xi’an, China – March 30, 2012 Highlights for Q4 2011: · Total revenue in the fourth quarter of 2011 increased 49.2% to $47.9 million from $32.1 million in the third quarter of 2011 and increased 32.8% from $36.1 million in the fourth quarter of 2010. · Total gross floor area (“GFA”) sales were] []
[Company Contact Mr. Ming Yin Vice President - Business Development China Biologic Products, Inc. Telephone: +86 10 6598 3099 Email: ir@chinabiologic.com www.chinabiologic.com China Biologics Board Has Elected David (Xiaoying) Gao as the New Chairman and Has Adopted a Series of Measures to Enhance China Biologics Corporate Governance BEIJING, April 2, 2012 /PRNewswire/ China Biologic Products, Inc. (NASDAQ: CBPO, China Biologic] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): April 2, 2012 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building, 19 Chaoyang Park Road Chaoyang District, Beijing 100125 Peoples Republic of China (+86) 10-6598-3111 (Former name or former]
[Company Contact Mr. Ming Yin Vice President - Business Development China Biologic Products, Inc. Telephone: +86 10 6598 3099 Email: ir@chinabiologic.com www.chinabiologic.com China Biologics Board Has Elected David (Xiaoying) Gao as the New Chairman and Has Adopted a Series of Measures to Enhance China Biologics Corporate Governance BEIJING, April 2, 2012 /PRNewswire/ China Biologic Products, Inc. (NASDAQ: CBPO, China Biologic] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): April 2, 2012 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building, 19 Chaoyang Park Road Chaoyang District, Beijing 100125 Peoples Republic of China (+86) 10-6598-3111 (Former name or former]
